Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1117-1124

  Noro, Rintaro ^a   Yoshimura, Akinobu ^a,b   Yamamoto, Kazuo ^a   Miyanaga, Akihiko ^a   Mizutani, Hideaki ^a   Minegishi, Yuji ^a   Seike, Masahiro ^a   Kubota, Kaoru ^a   Kosaihira, Seiji ^c   Hino, Mitsunori ^c   Ando, Masahiro ^d   Nomura, Koichiro ^e   Okano, Tetsuya ^f   Kobayashi, Kunihiko ^f   Uematsu, Kazutsugu ^g   Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^d Tsuboi Cancer Center Hospital   (Japan)

^e TOKYO METROPOLITAN HIROO HOSPITAL   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Alternating chemotherapy; Amrubicin; Cisplatin; Extensive stage small cell lung cancer; Irinotecan

Indexed keywords

AMRUBICIN; CISPLATIN; IRINOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; EXTENSIVE STAGE SMALL CELL LUNG CANCER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA;

EID: 84875884949     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO, Omura GA and Greco FA: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10(2): 282-291, 1992.
2. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M and Suemasu K: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 83(12): 855-861, 1991.
3. Arriagada R, Le Chevalier T, Pignon JP, Riviere A, Monnet I, Chomy P, Tuchais C, Tarayre M and Ruffie P: Initial chemotherapeutic doses and survival in patients with limited small cell lung cancer. N Engl J Med 329(25): 1848-1852, 1993.
4. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, Grayson J, Minna JD and Johnson BE: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 12(10): 2022-2034, 1994.
5. Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J and Gandara D: Randomized study of CODE versus alternating CAV/EP for extensive-stage small cell lung cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17(8): 2300-2308, 1999.
6. Goldie JH, Coldman AJ and Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66(3): 439-449, 1982.
7. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K and Takada M: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 10(8): 1225-1229, 1992.
8. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K and Fukuoka M: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16(3): 1068-1074, 1998.
9. Ando M, Kobayashi K, Yoshimura A, Kurimoto F, Seike M, Nara M, Moriyama G, Mizutani H, Hibino S, Gemma A, Okano T, Shibuya M and Kudoh S: Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 44(1): 121-127, 2004.
10. Yoshimura A, Noro R, Miyanaga A, Mizutani H, Kosaihira S, Minegishi Y, Seike M, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Gemma A and The East Japan Chesters Group: Combination Chemotherapy of Alternating Etoposide and Carboplatin with Weekly Administration of Irinotecan and Cisplatin in Extensive-Stage Small Cell Lung Cancer. Anticancer Res 32: 4473-4478, 2012.
11. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T and Yamaoka T: A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89(11): 1229-1238, 1998.
12. Yana T, Negoro S, Takada M, Yokota S, Takada Y, Sugiura T, Yamamoto H, Sawa T, Kawahara M, Katakami N, Ariyoshi Y and Fukuoka M: West Japan Thoracic Oncology Group: Phase II study of amrubicin in previously untreated patients with extensivedisease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Inevest New Drugs 25(3): 253-258, 2007.
13. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, Nishiwaki Y, Yokota S, Kawahara M, Saijo N, Fukuoka M and Ariyoshi Y: Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small cell lung cancer. Ann Oncol 16(3): 430-436, 2005.
14. Common Toxicity Criteria Manual, Common Toxicity Criteria, version 3 2006. (http://ctep.cancer.gov/reporting/ctc.html)
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216, 2000.
16. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T and Yamaoka T: A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89(11): 1229-1238, 1998.
17. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260(27): 14873-14878, 1985.
18. Hofmann GA and Mattern MR: Topoisomerase II in multiple drug resistance. Cytotechnology 12(1-3): 137-154, 1993.
19. Kaplan E and Gunduz U: Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance. Biomed Pharmacother 66(1): 29-35, 2012.
20. Takakuwa O, Oguri T, Ozasa H, Uemura T, Kasai D, Miyazaki M, Maeno K and Sato S: Over-expression of MDR1 in amrubicinol-resistant lung cancer cells. Cancer Chemother Pharmacol 68(3): 669-676, 2011.
21. Rasheed ZA and Rubin EH: Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22(47): 7296-7304, 2003.
22. Chrncik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L and Redinbo MR: Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol 339(4): 773-784, 2004.
23. Chavier D, Kegelaer G, Morjani H and Manfait M: Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin. J Pharm Sci 91(8): 1765-1775, 2002.
24. Schneider E, Horton JK, Yang CH, Nakagawa M and Cowan KH: Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54(1): 152-158, 1994.
25. Jensen PB, Holm B, Sorensen M, Christensen IJ and Sehested M: In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 75(6): 869-877, 1997.
26. Chavier D, Morjani H and Manfait M: Homocamptothecindaunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells. Breast Cancer Res Treat 73(2): 113-125, 2002.
27. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S and Saijo N: Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 346(2): 85-91, 2002.
28. Lara PN Jr., Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K and Gandara DR: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27(15): 2530-2535, 2009.
29. Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr., Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B and Sandler A: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24(13): 2038-2043, 2006.